STRM.BIO is a biotechnology company that uses extracellular vesicles to deliver gene therapy in a more efficient and practical manner.
STRM.BIO has raised $8.0M in total funding. The most recent round was Seed. The last funding was announced in January 2026.
STRM.BIO's investors include Blue Bay Capital Fund, Bill & Melinda Gates Foundation, Boehringer Ingelheim Venture Fund, Delos Capital, NYBC Ventures.
STRM.BIO is headquartered in Cambridge, United States.
STRM.BIO is a biotechnology company that uses extracellular vesicles to deliver gene therapy in a more efficient and practical manner.
STRM.BIO is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"STRM.BIO — Funding & Investors." VCBacked, January 7, 2026, https://www.vcbacked.co/company/strmbio. Accessed July 19, 2026.
VCBacked. (2026). STRM.BIO — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/strmbio
{{cite web |title=STRM.BIO — Funding & Investors |url=https://www.vcbacked.co/company/strmbio |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated